| Name | Title | Contact Details |
|---|---|---|
Alfred Chun |
Senior Director, Regulatory Compliance | Profile |
Jon Galli |
Deputy General Counsel | Profile |
Rushna Heneghan |
Corporate Vice President and Deputy General Counsel | Profile |
Matthew Daniel |
Corporate Senior Vice President, Legal Compliance and Deputy General Counsel | Profile |
Andy Griffin |
Corporate Vice President, IT Security and Compliance | Profile |
Enzon Pharmaceuticals Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Thomson Research Associates is a North York, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
BioIntervene, Inc. is a preclinical-stage biopharmaceutical company committed to the discovery and development of effective and non-addictive medicines for chronic pain and other chronic inflammatory and neurodegenerative disorders. The Company was founded in 2014 based on insights from research at Saint Louis University and the National Institutes of Health (NIH). BioIntervene`s founding team has pioneered the understanding of adenosine A3 receptor biology, with a focus on developing first-in-class, selective adenosine A3 receptor agonists. California, United States Read more at CB Insights: https://www.cbinsights.com/company/biointervene
At Ensoma, we believe every person, no matter where they are in the world, should have access to innovative technologies that are changing the way we treat disease.
We are a global biopharmaceutical company leveraging courageous science, creativity, and compassion to deliver life-changing therapies. By pioneering targeted C3 therapies, we aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology.